| Chairman |
|
Dan Eldar(formerly known as Perlmutter) |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman: Dan Eldar(formerly known as Perlmutter) Chief Executive Officer: Su Weiguo Acting Chief Executive Officer: Cheng Chig Fung Johnny Non-executive Director: Edith Shih, Yang Ling Independent Non-executive Director: Renu Bhatia, Hu Chaohong, Wong Tak Wai Alvin, Tan Shao Weng Daniel.
|
| Principle Business |
|
The Group is principally engaged in development and commercialization of drugs for the treatment of patients with cancer and immunological diseases, and drug marketing and distribution business in the PRC. |
| Related Indexes |
| HKEX Tech 100 Index | Hang Seng Healthcare Index | | Hang Seng Composite Index | Hang Seng Biotech Index | | Hang Seng Healthcare Industry Index | Hang Seng Composite MidCap Index |
|
| Major Shareholders |
| CK HUTCHISON HOLDINGS LIMITED | 332,574,650 | 38.12% | 2025/12/31 |
|
| Related Stocks |
|